NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA.
Rasmussen DGK, et al.
J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028. Epub 2022 Dec 14.
J Hepatol. 2023.
PMID: 36526000
Free article.
Review.
Biomarkers have the potential to accelerate drug development, as early indicators of improved clinical response, to improve patient safety, and for personalised medicine. ...This paper outlines how biomarkers can accelerate drug development, and reviews the lessons …
Biomarkers have the potential to accelerate drug development, as early indicators of improved clinical response, to improve patient s …